Signal: Wegovy cuts cardiovascular risk by 20% for heart disease patients
Novo Nordisk’s blockbuster weight-loss drug Wegovy may reduce the risk of heart attack before the weight loss effects take place,…
Novo Nordisk
-
-
Novo Nordisk to close kidney outcomes trial for Ozempic
Novo Nordisk has announced that it will stop the kidney outcomes trial for the company’s blockbuster drug, Ozempic, even after…
-
Signal: Novo Nordisk market cap higher than Danish GDP due to obesity drugs
Novo Nordisk, manufacturer of GLP-1 antagonist drugs Wegovy and Ozempic, now has a higher market capitalisation than the yearly GDP…
-
Novo Nordisk acquires Ziylo in a deal valued up to $800m
Novo Nordisk has acquired 100% of shares in UK-based biotechnology firm Ziylo under a potential deal worth more than $800m.…
